The CXCR2 Antagonist, SCH-527123, Shows Antitumor Activity and Sensitizes Cells to Oxaliplatin in Preclinical Colon Cancer Models

Y. Ning, M. J. Labonte, W. Zhang, P. O. Bohanes, A. Gerger, D. Yang, L. Benhaim, D. Paez, D. O. Rosenberg, K. C. Nagulapalli Venkata, S. G. Louie, N. A. Petasis, R. D. Ladner, H.-J. Lenz
  • Molecular Cancer Therapeutics, March 2012, American Association for Cancer Research (AACR)
  • DOI: 10.1158/1535-7163.mct-11-0915
The author haven't finished explaining this publicationThe author haven't finished explaining this publication
Read Publication

http://dx.doi.org/10.1158/1535-7163.mct-11-0915

The following have contributed to this page: Professor Nicos A. Petasis